The use of antiretroviral drugs has turned HIV/AIDS from a fatal disease to one that can, in many cases in the US, be controlled. But these drugs are not a cure. That's why the governing Board of the California Institute for Regenerative Medicine (CIRM) voted to approve investing $6.85 million in a therapy that aims … Continue reading Funding a Clinical Trial for a Functional Cure for HIV
CRISPR
A better, faster, more effective way to edit genes
Clinical fellow Brian Shy talks with postdoctoral scholar Tori Yamamoto in the Marson Lab at Gladstone Institutes on June 8th, 2022. Photo courtesy Gladstone Institutes. For years scientists have been touting the potential of CRISPR, a gene editing tool that allows you to target a specific mutation and either cut it out or replace it … Continue reading A better, faster, more effective way to edit genes
First Patient Dosed in Phase 1 Clinical Trial for T1D
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D
Tiny tools for the smallest of tasks, editing genes
YOU CAN LISTEN TO THIS BLOG AS AN AUDIOCAST ON SPOTIFY Developing new tools to edit genes Having the right tools to do a job is important. Try using a large screwdriver to tighten the screws on your glasses and you quickly appreciate that it’s not just the type of tool that’s important, it’s also … Continue reading Tiny tools for the smallest of tasks, editing genes
CIRM-catalyzed spinout files for IPO to develop therapies for genetic diseases
Graphite Bio, a CIRM-catalyzed spinout from Stanford University that launched just 14 months ago has now filed the official SEC paperwork for an initial public offering (IPO). The company was formed by CIRM-funded researchers Matt Porteus, M.D., Ph.D. and Maria Grazia Roncarolo, M.D. Six years ago, Dr. Porteus and Dr. Roncarolo, in conjunction with Stanford … Continue reading CIRM-catalyzed spinout files for IPO to develop therapies for genetic diseases
Three UC’s Join Forces to Launch CRISPR Clinical Trial Targeting Sickle Cell Disease
Sickle shaped red blood cells The University of California, San Francisco (UCSF), in collaboration with UC Berkeley (UCB) and UC Los Angeles (UCLA), have been given permission by the US Food and Drug Administration (FDA) to launch a first-in-human clinical trial using CRISPR technology as a gene-editing technique to cure Sickle Cell Disease. This research … Continue reading Three UC’s Join Forces to Launch CRISPR Clinical Trial Targeting Sickle Cell Disease
Scientists use stem cells to create Neanderthal-like “mini-brain”
Alysson R. Muotri, Ph.D. The evolution of modern day humans has always been a topic that has been shrouded in mystery. Some of what is known is that Neanderthals, an archaic human species that lived on this planet up until about 11,700 years ago, interbred with our species (Homo sapiens) at some point in time. … Continue reading Scientists use stem cells to create Neanderthal-like “mini-brain”
Progress in the fight against Sickle Cell Disease
Marissa Cors, sickle cell disease patient advocate Last November Marissa Cors, a patient advocate in the fight against Sickle Cell Disease (SCD), told the Stem Cellar “A stem cell cure will end generations of guilt, suffering, pain and early death. It will give SCD families relief from the financial, emotional and spiritual burden of caring … Continue reading Progress in the fight against Sickle Cell Disease
Graphite Bio launches and will prepare for clinical trial based on CIRM-funded research
Josh Lehrer, M.D., CEO of Graphite Bio This week saw the launch of the 45th startup company enabled by CIRM funding of translational research at California academic institutions. Graphite Bio officially launched with the help of $45M in funding led by bay area venture firms Versant Ventures and Samsara BioCapital to spinout a novel CRISPR … Continue reading Graphite Bio launches and will prepare for clinical trial based on CIRM-funded research
Gladstone scientists respond to coronavirus pandemic
In these uncertain times, we often look to our top scientists for answers as well as potential solutions. But where does one begin to try and solve a problem of this magnitude? The first logical step is building on the supplies currently available, the work already accomplished, and the knowledge acquired. This is the approach … Continue reading Gladstone scientists respond to coronavirus pandemic
The Stem Cellar 